{"entity":{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","aka":["KRASCENDO 3"],"tldr":"A phase 3 trial of Divarasib, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT07541170 by Hoffmann-La Roche, with 400 participants planned, started 2026-09-30 and due to reach its primary completion in 2032-01-31. Interventions recorded: Divarasib, Pembrolizumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07541170","url":"https://clinicaltrials.gov/study/NCT07541170"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","kras-g12c-nsclc","resectable-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["divarasib","pembrolizumab","nivolumab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07541170","phase":"3","setting":"A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT07541170","source":"https://clinicaltrials.gov/study/NCT07541170","fetchedAt":"2026-10-07T16:55:48.292Z","studySha256":"a29a0a6d116131945a5665ec2e643d68e333f4b1b347d46d8c4e89a5b5eb2185","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-09","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":19,"recruitingSiteCount":19,"countries":["Argentina","Brazil","Hong Kong","Italy","South Korea","United States"]}],"started":"2026-09-30","startedType":"estimated","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07541170/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}